Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol + propylene glycol
- Development stage
- Unknown
- Lead developer
- Navana Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Syscol is an ophthalmic lubricant (artificial tears) formulation containing polyethylene glycol 400 (0.4%) and propylene glycol (0.3%). Developed and marketed by Navana Pharmaceuticals, it is used for the temporary relief of burning, irritation, and discomfort caused by dry eye syndrome. The active ingredients act as demulcents and lubricants on the ocular surface, increasing the viscosity and water-retention of the tear film to reduce friction, stabilize the pre-corneal tear film, and protect the eye from further irritation.
- Brand names
- Syscol
- Other names
- polyethylene glycol 400 + propylene glycol
Beyond the preview
Go deeper on polyethylene glycol + propylene glycol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol + propylene glycol.